ASCO published recommendations on germline and somatic testing of ovarian cancer
A new, evidence-based guideline released by the American Society of Clinical Oncology (ASCO) provides recommendations on genetic and tumor testing
Meta-analysis demonstrates significantly improved patient outcomes in major depressive disorder (MDD)
GeneSight® cohort outperforms treatment-as-usual (TAU) cohort in every endpoint
NCCN® prostate cancer guidelines say tumor-based molecular testing is appropriate for intermediate and high-risk disease
Updated prostate cancer guidelines double the number of risk categories considered appropriate for molecular-based testing.
ASCO issued evidence-based guidelines for molecular biomarkers in localized prostate cancer
The guidelines include recommendations regarding the clinical use and indications of certain prostate cancer biomarkers.
Advancing precision medicine for pancreatic cancer patients, Myriad obtains expanded BRACAnalysis CDx® indication
The U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx as a companion diagnostic test to Lynparza® (olaparib), a PARP inhibitor.
GeneSight test significantly improved outcomes in depressed patients using 6-item Hamilton Scale
Patients who received the GeneSight test had significantly improved clinical outcomes by week 8 (HAM-D6)
American College of Rheumatology (ACR) includes Vectra® in their new recommendations on disease activity measures
Evaluation of its performance and feasibility results in Vectra meeting standards for regular use in clinical settings
NCCN® expands testing criteria in Clinical Practice Guideline; Elevates importance of pancreatic cancer testing
Testing criteria for high penetrance genes moves beyond BRCA1/2; Simplifies decision process
New study demonstrates patients with MDD taking antidepressants with gene-drug interactions benefit from GeneSight
Published online in Journal of Clinical Psychiatry, Thase et al. assessed patients who entered the GUIDED study on medications with predicted gene-drug interactions
Dermatopathology experts publishing in SKIN provide guidance for the appropriate use of diagnostic gene expression profiling (GEP) in melanoma
In their guidance, myPath® Melanoma earned their highest recommendation, “A-strength,” for a clinical scenario which mirrors myPath’s intended use.
How does Prolaris® improve health outcomes?
Active surveillance (AS) is appropriate for patients with low-risk prostate cancer.
EndoPredict® accurately estimates absolute chemotherapy benefit at 10 years
Data published in the ASCO Journal of Precision Oncology further demonstrates EndoPredict’s ability to accurately predict absolute chemotherapy benefit
Kroger Health and Myriad Genetics launch pilot to improve treatment of depression
GeneSight® pharmacogenomic test now available to Kroger Prescription Plan members
New data demonstrate EndoPredict® breast cancer prognostic test’s ability to predict chemotherapy benefit and identify patients who can safely forgo extended endocrine therapy
Findings promote reduction in overtreatment in ER+/HER2- breast cancer patients
Weighing Clinical and Patient Experience with Hereditary Pan-Cancer Panel Testing
Among patients who carried a pathogenic variant (12%), one third of these clinically relevant results were not suspected upon pretest expert assessment
Medicare Issues Favorable Decision for myPath® Melanoma
Diagnostic test drives reduction in overtreatment by providing definitive diagnosis for suspicious skin lesion biopsies
NCCN® elevates its prostate cancer germline testing reference to RECOMMENDED for all risk groups with qualification for Very Low, Low and Intermediate
The National Comprehensive Cancer Network (NCCN) recently updated its Prostate Cancer Guidelines